千金药业(600479.SH)：补血益母丸获批国家中药保护品种

Core Viewpoint - Qianjin Pharmaceutical (600479.SH) has received approval from the National Medical Products Administration for its product, Bu Xue Yi Mu Wan, to be the first Chinese medicine to be classified as a secondary protected variety, enhancing the company's intellectual property protection and market competitiveness in postpartum recovery medication [1] Group 1 - The National Medical Products Administration published the announcement on January 20, 2026, approving Bu Xue Yi Mu Wan as the first secondary protected variety of traditional Chinese medicine [1] - Bu Xue Yi Mu Wan is recognized as a national basic drug, a Class A medical insurance product, and an exclusive product, and is included in several clinical application guidelines and textbooks [1] - The product is indicated for conditions related to postpartum abdominal pain due to deficiency of both qi and blood, as well as blood stasis [1] Group 2 - The approval of Bu Xue Yi Mu Wan is expected to positively impact the company's production and operations by strengthening its market position in the postpartum recovery medication sector [1]